Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-days Versus 14 Days of Antibiotics Therapy for VAP Due to Drug Resistant Acinetobacter Baumanii
NCT03477292Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Mar 2018
- Primary completion
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised trial of colistin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Relapses of Ventilator Associated Pneumonia at 28 days. Started Mar 2018; status: completed.
02
Drugs
colistin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03477292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477292.